Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study
- 1 March 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (7), 767-772
- https://doi.org/10.1200/jco.2006.05.8172
Abstract
The role of high-degree microsatellite instability (MSI-H) as a marker to predict benefit from adjuvant chemotherapy remains unclear. To help define its impact, we conducted an analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) patients who were randomly assigned to a surgery-alone group (untreated cohort) and patients assigned to an adjuvant fluorouracil (FU) -treated group (treated cohort). MSI-H and other potential markers were assessed (TGF-BRII, p53, thymidylate synthase, and Ki67). In all, 98 (18.1%) of 542 patients exhibited MSI-H, and there was a strong inverse relationship between MSI-H and mutant p53 status (P < .001). The prognostic analyses showed increased recurrence-free survival (RFS) for MSI-H patients versus MSS/MSI-L patients (P = .10), but showed no difference in overall survival (OS; P = .67). There was a potential interaction between MSI-H and mutant p53 in terms of improved RFS (P = .03). In the predictive marker analysis, we observed no interaction between MSI status and treatment for either RFS (P = .68) or OS (P = .62). Hazard ratios (HR) for RFS for MSI-H versus MSS/MSI-L patients were 0.77 (95% CI, 0.40 to 1.48) in the untreated-patients group and 0.60 (95% CI, 0.30 to 1.19) in the treated-patients group. HRs for OS were 0.82 (95% CI, 0.44 to 1.51) and 1.02 (95% CI, 0.56 to 1.85) for the respective groups. There was a trend toward improved RFS in patients with MSI-H and mutant p53. These results do not support the use of MSI-H as a predictive marker of chemotherapy benefit.Keywords
This publication has 26 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.Journal of Clinical Oncology, 1998
- Prognostic Significance of DNA Replication Errors in Young Patients With Colorectal CancerAnnals of Surgery, 1998
- Better survival rates in patients with MLH1-associated hereditary colorectal cancerGastroenterology, 1996
- Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final ReportAnnals of Internal Medicine, 1995
- Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesisNature, 1993
- Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technologyBritish Journal of Cancer, 1993
- Microsatellite Instability in Cancer of the Proximal ColonScience, 1993
- Clues to the Pathogenesis of Familial Colorectal CancerScience, 1993
- Multiple primary cancers and prolonged survivalDiseases of the Colon & Rectum, 1978